NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326

CompletedN/A

Sponsor: AstraZeneca

Conditions: Non-small Cell Lung Cancer

Countries: China

This is a multi-center, prospective, non-interventional study. The study will enroll about 1700 Chinese patients diagnosed as NSCLC and treated with osimertinib at least one dose. The objective of this non-interventional study is to monitor the safety profile of osimertinib in Chinese NSCLC patients in real world clinical practice.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
* Patients histologically or cytologically diagnosed as NSCLC
* Eligible for osimertinib treatment per the judgement of the treating physician in clinical practice
* Received at least one dose of osimertinib

Exclusion Criteria:

• Enrollment in other on-going studies, which prohibit any participation in this non-interventional study

Locations (29)

Beijing, China
Chengde, China
Chengdu, China
Dingzhou, China
Fuzhou, China
Ganzhou, China
Guangzhou, China
Guangzhou, China
Guangzhou, China
Guangzhou, China
Hangzhou, China
Hangzhou, China
Hangzhou, China
Hangzhou, China
Hangzhou, China
Harbin, China
Huanghua, China
Jinan, China
Linhai, China
Nanchang, China
Shanghai, China
Shijiazhuang, China
Suzhou, China
Taiyuan, China
Tianjin, China
Weihai, China
Wuhan, China
Wuhan, China
Zhuji, China